Healthcare Global Enterprises Limited has informed the Exchange regarding Appointment of Dr Manish Mattoo as Executive Director of the company w.e.f. Jun 30, 2025.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 2.0 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG has completed a major change of control. Former promoter Aceso Company Pte. Ltd. has sold roughly 54% of the company to KKR-linked entities — Hector Asia Holdings II (~51.41%) and KIA EBT II Scheme 1 (~0.18%) — and has been moved to the public shareholder category. Founder Dr. B.S. Ajaikumar continues as promoter with 10.40%. Two nominee directors of the seller resigned and were replaced by two KKR nominees: Simrun Mehta (MD, KKR India Advisors) and Akshay Tanna (Head of KKR India Private Equity). Dr. B.S. Ajaikumar has been re-designated as Non-Executive Chairman until June 30, 2030, and founder family member Anjali Ajaikumar Rossi continues on the board as a Non-Executive Director. Existing CEO Meghraj Arvindrao Gore has resigned effective June 30, 2025, and will be replaced by Dr. Manish Mattoo, a former Regional CEO at Apollo Hospitals, who will also serve as Executive Director. The Articles of Association have been amended to give the new promoter reserved matter and information rights.
This is a transformative event — KKR is now the controlling shareholder and has brought in its own board nominees, a new CEO with hospital operations experience, and governance changes. Shareholders should expect a shift in strategic direction under KKR's ownership, with the founder continuing in a non-executive oversight role. Stock sentiment may react to both the change of control and the leadership transition.